SPARCL1 Expression Increases With Preoperative Radiation Therapy and Predicts Better Survival in Rectal Cancer Patients

Kotti, Angeliki; Holmqvist, Annica; Albertsson, Maria; Sun, Xiaoying

doi:10.1016/j.ijrobp.2013.12.041

Cited by 7 publications

(7 citation statements)

References 22 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The almost exclusive expression of SPARCL1 in ECs was the subject of controversy in previous studies (24,39). However, our results are strongly supported by the consistent confirmation we obtained with 3 different methods (permanent IHC, immunofluorescence IHC, and ISH) and the agreement with studies by others in humans and mouse models (11,57,58).…”

Section: Discussionsupporting

confidence: 91%

Matricellular protein SPARCL1 regulates tumor microenvironment–dependent endothelial cell heterogeneity in colorectal carcinoma

Naschberger¹,

Liebl²,

Schellerer³

et al. 2016

Journal of Clinical Investigation

View full text Add to dashboard Cite

Section: Discussionsupporting

confidence: 91%

Matricellular protein SPARCL1 regulates tumor microenvironment–dependent endothelial cell heterogeneity in colorectal carcinoma

Naschberger¹,

Liebl²,

Schellerer³

et al. 2016

Journal of Clinical Investigation

View full text Add to dashboard Cite

“…Abnormal expression of the SPARCL1 gene and protein have been reported during the development and progression of many types of cancer, including non-small cell lung carcinomas [23], prostate carcinoma [24], colorectal carcinoma [14-17], gastric cancer [18, 19], pancreatic cancer [9], hepatocellular carcinoma [5], osteosarcoma [25] and gliomas [26]. The diverse expression pattern of SPARCL1 in different human malignancies suggests that it might play different roles in tumor biology based on the tumor type [2].…”

Section: Discussionmentioning

confidence: 99%

“…The diverse expression pattern of SPARCL1 in different human malignancies suggests that it might play different roles in tumor biology based on the tumor type [2]. In the field of GI malignancies, most studies have indicated that down-regulation of the SPARCL1 protein leads to a poor prognosis in patients; however, the conclusions are controversial [5, 9, 16, 17]. Therefore, we performed this meta-analysis to explore the role of the SPARCL1 protein in GI malignancies.…”

Section: Discussionmentioning

confidence: 99%

SPARCL1, a Novel Prognostic Predictive Factor for GI Malignancies: a Meta-Analysis

Cui

Zheng

et al. 2017

Cell Physiol Biochem

View full text Add to dashboard Cite

Background/Aims: Secreted protein acidic and rich in cysteines-like 1 (SPARCL1) is abnormally expressed in gastrointestinal (GI) malignancies. However, the correlation between SPARCL1 expression and the prognosis of patients remains unknown. Therefore, we performed a meta-analysis to investigate the potential value of SPARCL1 as a prognostic predictive marker for GI malignancies. Methods: The PubMed, Embase, EBSCO, CNKI, and Wanfang databases were systematically searched for studies examining SPARCL1 and clinicopathological features, including the prognoses of patients. Hazard ratios (HRs) and odds ratios (ORs) from individual studies were calculated and pooled using a random-effects or fix-effects model. Heterogeneity and publication bias analyses were performed. Results: Data from 8 studies, including a total of 2,356 patients, were summarized. The expression of SPARCL1 suggested a better prognosis (HR=0.57, 95% CI: 0.445-0.698, P=0.000) and was associated with clinicopathological features of GI malignancies, including distant metastasis (OR=0.44, 95% CI: 0.23-0.85, P=0.014), lymph node metastasis (OR=0.56, 95% CI: 0.39–0.81, P=0.002) and tumor differentiation (OR=2.21, 95% CI: 1.82–2.69, P=0.000). Subgroup analyses based on cancer type revealed that the expression of SPARCL1 had no effect on lymph node metastasis in colorectal cancer, and it did not influence tumor differentiation in gastric cancer. Egger’s test showed no evidence of publication bias (all P>0.05). Conclusion: SPARCL1 could be a novel prognostic predictive factor for GI malignancies. The expression of SPARCL1 could influence the clinicopathological features of GI malignancies. Further large-scale studies are essential to confirm SPARCL1’s prognostic predictive value, and more fundamental experimental studies are needed to illustrate the mechanisms.

show abstract

“…The overexpression of general receptor for the phosphoinositides 1‐associated scaffold protein (GRASP) might inhibit proliferation and invasion of HCC cells . In patients with rectal cancer, secreted protein acidic and rich in cysteine‐like 1 (SPARCL1) expression is associated with better responses to preoperative radiation therapy and predicts better survival . Junctional Adhesion Molecule 3 (JAM3) could suppress the clonogenicity and migration capability of colorectal cancer cells .…”

Section: Discussionmentioning

confidence: 99%

“…34 In patients with rectal cancer, secreted protein acidic and rich in cysteine-like 1 (SPARCL1) expression is associated with better responses to preoperative radiation therapy and predicts better survival. 35 Junctional Adhesion Molecule 3 (JAM3) could suppress the clonogenicity and migration capability of colorectal cancer cells. 36 The tumor suppressive effects of these co-expressed genes might help to explain the association between FOXF1 expression and favorable RFS in classical PTC.…”

Section: Discussionmentioning

confidence: 99%

Bioinformatic analysis of the prognostic value and potential regulatory network of FOXF1 in papillary thyroid cancer

2019

BioFactors

View full text Add to dashboard Cite

FOXF1 belongs to the forkhead family of transcription factors. In this study, we aimed to explore the expression profile of FOXF1 in papillary thyroid cancer (PTC) and corresponding adjacent normal tissues, by using data from The Cancer Genome Atlas‐Thyroid Cancer (TCGA‐THCA) and The Genotype‐Tissue Expression (GTEx) project. Also, we studied its prognostic significance in PTC and its potential regulatory network. Results showed that FOXF1 expression was significantly lower in PTC tissues compared with adjacent normal tissues. Subgroup analysis only confirmed the downregulation in classical histological variant, but not in tall‐cell and follicular variants. FOXF1 downregulation was associated with advanced T stages, positive nodal invasion, and advanced pathological stages of the classical variants. FOXF1 expression might be a fair prognostic marker in terms of recurrence, which independently predicted favorable RFS (HR:0.114, 95%CI: 0.045–0.289, p < .001). We examined FOXF1 somatic mutations, gene‐level copy number alterations (CNAs) and the methylation status of 57 CpG sites in more than 350 classical PTC cases. However, no expression‐related genetic and epigenetic alterations were identified. Based on 20,048 genes with RNA‐seq data, we identified 16 genes that showed strongly positive co‐expression (Pearson's r ≥ 0.6) with FOXF1. Available evidence showed that some of the genes have well‐characterized tumor suppressive effects. We hypothesized that some of these genes might be the upstream regulators or downstream effectors of FOXF1 in classical PTC. In conclusion, FOXF1 mRNA was typically downregulated in classical PTC. Its expression might be a specific and independent prognostic biomarker in terms of RFS in classical PTC patients.

show abstract

SPARCL1 Expression Increases With Preoperative Radiation Therapy and Predicts Better Survival in Rectal Cancer Patients

Cited by 7 publications

References 22 publications

Matricellular protein SPARCL1 regulates tumor microenvironment–dependent endothelial cell heterogeneity in colorectal carcinoma

Matricellular protein SPARCL1 regulates tumor microenvironment–dependent endothelial cell heterogeneity in colorectal carcinoma

SPARCL1, a Novel Prognostic Predictive Factor for GI Malignancies: a Meta-Analysis

Bioinformatic analysis of the prognostic value and potential regulatory network of FOXF1 in papillary thyroid cancer

Contact Info

Product

Resources

About